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were in the range of those after balloon dilatation followed by DES – stenting (8.3 %).
At one year plain balloon dilation (13.4 %) had a similar rate of re - restenosis as cutting
balloon dilatation (13.4%) and balloon dilatation followed by implantation of a BMS
(15.4 %).
Conclusion: The reported rate of re - restenosis in ISR was generally low but differ
largely according to the applied therapy.
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Background: Recently, late restenosis after drug-eluting stent (DES) has been
reported. However, the impact of DES type and timing remains unclear. Thus, we
evaluated the restenosis pattern of three different drug-eluting stent ; sirolimus-eluting
stent (SES), paclitaxel-eluting stent (PES), and zotarolimus eluting stent (ZES) in
midterm (8 months) and lateterm (20 months).
Methods: From November 2002 to October 2009, 4368 consecutive patients (7546
lesions) were treated with SES and PES and ZES (SES, 5924 lesions; PES, 1405
lesions; ZES, 217 lesions) and performed midterm follow-up coronary angiography
(f/u CAG) at 6 to 8 months after implantation (f/u rate, 81.6% [6156/7546]). Of these,
4610 lesions without restenosis underwent late f/u CAG at 12 months after early f/u
(f/u rate, 86.2%). Early restenosis was defined as restenosis at midterm f/u and late
restenosis as restenosis at late f/u without early restenosis. Restenosis types are
classified into 1 focal pattern with 4 types and 3 diffuse patterns: pattern Ι (focal: type
IA, gap; type IB, edge; type IC, body; type ID, multifocal), pattern II (diffuse in-stent),
pattern III (diffuse proliferative), and pattern IV (total occlusion).
Results: Data are shown in the table.
Restenosis pattern with Mehran Classification of SES and PES and ZES
*1;SES vs PES, *2;SES vs ZES, *3;PES vs ZES
Conclusion: Restenosis pattern of drug-eluting stent could be depend on stent type
and timing of restenosis.
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Background: To evaluate the safety and effectiveness of the Elixir DESyneTM BD
Novolimus-Eluting Coronary Stent System (CSS) with a Bioabsorbable polymer
compared to the Endeavor Zotarolimus-Eluting Coronary Stent System through the
assessment of clinical, angiographic, and IVUS endpoints.
Methods: 149 patients, were randomized 3:1 to receive either the Elixir DESyne BD
Novolimus-eluting CSS loaded with 5mcg per mm of stent length of Novolimus, a
sirolimus metabolite, eluted via a bioabsorbable polylactide-based polymer, or to
Endeavor Zotarolimus-eluting CSS loaded with 10mcg per mm of stent length of
Zotarolimus eluted via a durable phosphoryl choline polymer. All patients were
analyzed for the primary endpoint of in-stent late lumen loss assessed by QCA at 6
months. Moreover, all patients underwent evaluation for the secondary endpoints which
include Device-oriented Composite Endpoint (DoCE) defined as: cardiac death, MI
not clearly attributable to a non-intervention vessel, and clinically-indicated target
lesion revascularization at 1, 6, 9, and 12 months and annually through 5 years,
clinically-indicated Target Lesion Revascularization (TLR), and Clinically-indicated
Target Vessel Revascularization (TVR). Lesions were also evaluated for angiographic
endpoints at 6 months including: in-lesion late lumen loss, percent diameter stenosis,
minimal lumen diameter post procedure and at 6 months, angiographic binary
restenosis (≥50%), and stent thrombosis. A subset of patients underwent intravascular
ultrasound (IVUS) evaluation including in-stent volumetric neointimal burden and
percent (%) neointimal obstruction at 6 months.
Results: Clinical results through 6 months, as well as the primary endpoint of in-stent
late lumen loss by QCA at 6 months with additional angiographic and IVUS results,
will be presented.
Conclusion: Clinical results through 6 months, as well as the primary endpoint of in-
stent late lumen loss by QCA at 6 months with additional angiographic and IVUS
results will be presented.
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Background: Few data exist that describe percutaneous coronary intervention (PCI)
benefits in COURAGE-like stable coronary disease populations receiving a drug
eluting stent (DES). The aim was to compare, for the first time, clinical and health
status outcomes in COURAGE-like patients following PCI exclusively using a DES,
the XIENCE V® everolimus-eluting stent (Abbott Vascular, Santa Clara, CA).
Methods: This was a prospective, multi-center, unrestricted, real-world study of
consecutively-enrolled patients (n=4797) who had a least 1 valid Seattle Angina
Questionnaire score at baseline. Quality of Life (QoL) scores were analyzed using
Two-Way ANOVA (Mixed Model-Repeated Measures) with group (COURAGE-like
matched for symptom class, coronary anatomy, EF and BP vs. a more complex non
COURAGE-like) and visit (baseline, 180 days, 365 days) as fixed factors and group
by visit as an interaction effect.
Results: See Table.
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